BR112013009643A2 - método para preparar n-(3-amino-quinoxalin-2-il)-sulfonamidas substituídas e seus intermediários n-(3-cloo-quinoxalin-2-il)-sulfonamidas - Google Patents

método para preparar n-(3-amino-quinoxalin-2-il)-sulfonamidas substituídas e seus intermediários n-(3-cloo-quinoxalin-2-il)-sulfonamidas

Info

Publication number
BR112013009643A2
BR112013009643A2 BR112013009643A BR112013009643A BR112013009643A2 BR 112013009643 A2 BR112013009643 A2 BR 112013009643A2 BR 112013009643 A BR112013009643 A BR 112013009643A BR 112013009643 A BR112013009643 A BR 112013009643A BR 112013009643 A2 BR112013009643 A2 BR 112013009643A2
Authority
BR
Brazil
Prior art keywords
sulfonamides
quinoxalin
amino
intermediates
chloro
Prior art date
Application number
BR112013009643A
Other languages
English (en)
Inventor
Danig Pohin
Dominique Swinnen
Original Assignee
Merck Serono S A Geneva
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono S A Geneva filed Critical Merck Serono S A Geneva
Publication of BR112013009643A2 publication Critical patent/BR112013009643A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C07D241/22—Benzenesulfonamido pyrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

método para preparar n-(3-amino-quinoxalin-2-il)-sulfonamidas substituídas e seus intermediários n-(3-cloo-quinoxalin-2-il)-sulfonamidas. a presente invenção refere-se a uma nova síntese para preparar n-(3-amino-quinoxalin-2-il)-sulfonamidas de fórmulas gerais (i) ou (i<39>) e sulfonamidas intermediárias de fórmula (ii) ou (ii<39>):
BR112013009643A 2010-10-20 2011-10-18 método para preparar n-(3-amino-quinoxalin-2-il)-sulfonamidas substituídas e seus intermediários n-(3-cloo-quinoxalin-2-il)-sulfonamidas BR112013009643A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10188170 2010-10-20
US201061424933P 2010-12-20 2010-12-20
PCT/EP2011/068152 WO2012052420A1 (en) 2010-10-20 2011-10-18 Method for preparing substituted n-(3-amino-quinoxalin-2-yl)-sulfonamides and their intermediates n-(3-chloro-quinoxalin-2-yl)sulfonamides

Publications (1)

Publication Number Publication Date
BR112013009643A2 true BR112013009643A2 (pt) 2016-07-19

Family

ID=43587363

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013009643A BR112013009643A2 (pt) 2010-10-20 2011-10-18 método para preparar n-(3-amino-quinoxalin-2-il)-sulfonamidas substituídas e seus intermediários n-(3-cloo-quinoxalin-2-il)-sulfonamidas

Country Status (11)

Country Link
US (1) US20130211076A1 (pt)
EP (1) EP2630130A1 (pt)
JP (1) JP2013540141A (pt)
KR (1) KR20130141528A (pt)
CN (1) CN103270027A (pt)
AU (1) AU2011317675A1 (pt)
BR (1) BR112013009643A2 (pt)
CA (1) CA2815107A1 (pt)
EA (1) EA201390582A1 (pt)
MX (1) MX2013004289A (pt)
WO (1) WO2012052420A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010048800A1 (de) * 2010-10-20 2012-05-10 Merck Patent Gmbh Chinoxalinderivate
CN110698418B (zh) * 2019-09-11 2022-07-01 广西师范大学 一种3-芳胺基喹喔啉-2-甲酰胺类衍生物及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO111459B (ro) * 1993-01-21 1996-10-31 Sc Sintofarm Sa Procedeu de obținere a sulfachinoxalinei
WO2003051870A1 (en) 2001-12-18 2003-06-26 Astrazeneca Ab Novel compounds
AU2003290346A1 (en) 2002-12-24 2004-07-22 Biofocus Plc Compound libraries of 2,3-substituted pyrazine derivatives capable of binding to g-protein coupled receptors
SE0302304D0 (sv) 2003-08-27 2003-08-27 Astrazeneca Ab Novel compounds
RU2453540C2 (ru) 2005-04-21 2012-06-20 Лаборатуар Сероно С.А. 2,3-замещенные пиразинсульфонамиды в качестве ингибиторов crth2
WO2007023186A1 (en) * 2005-08-26 2007-03-01 Laboratoires Serono S.A. Pyrazine derivatives and use as pi3k inhibitors
JP5270353B2 (ja) 2005-10-07 2013-08-21 エクセリクシス， インク． ホスファチジルイノシトール３−キナーゼインヒビターとその使用方法
AU2007284562B2 (en) * 2006-08-16 2013-05-02 Exelixis, Inc. Using PI3K and MEK modulators in treatments of cancer
US8614215B2 (en) 2007-02-22 2013-12-24 Merck Serono Sa Quinoxaline inhibitors of phosphoinositide-3-kinases (PI3Ks)
WO2008127594A2 (en) 2007-04-11 2008-10-23 Exelixis, Inc. Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer

Also Published As

Publication number Publication date
MX2013004289A (es) 2013-10-25
CN103270027A (zh) 2013-08-28
KR20130141528A (ko) 2013-12-26
CA2815107A1 (en) 2012-04-26
AU2011317675A1 (en) 2013-05-02
WO2012052420A1 (en) 2012-04-26
US20130211076A1 (en) 2013-08-15
JP2013540141A (ja) 2013-10-31
EP2630130A1 (en) 2013-08-28
EA201390582A1 (ru) 2013-09-30

Similar Documents

Publication Publication Date Title
CY1123958T1 (el) Μεθοδος παρασκευης παραγωγων και ενδιαμεσων καρβαμοϋλπυριδονης
CY1122350T1 (el) Μεθοδος παρασκευης ινγενολ-3-αγγελικου
ECSP12011581A (es) Inhibidores de bace
UA111626C2 (uk) Похідні дигідрохінолін-2-ону
CO6852084A2 (es) Nuevos compuestos sustituidos con halógeno
CR20130501A (es) Derivados novedosos de cefalosporinas y composiciones farmacéuticas de estos
CR11776A (es) Inhibidores de bace
EA201390877A1 (ru) Замещенные 6,6-конденсированные азотсодержащие гетероциклические соединения и их применение
EA201490474A1 (ru) Аминохиназолины в качестве ингибиторов киназ
BR112012021865A2 (pt) derivados de ceto benzofurano, assim com o respectivo processo de síntese e os intermediários.
BRPI1012638B8 (pt) métodos e intermediários para preparar agentes farmacêuticos
UY32013A (es) Nuevo procedimiento de síntesis de la agomelatina
ME00928B (me) Novi postupak za sintezu agomelatina
EA201101675A1 (ru) Спироэпоксиды как промежуточные продукты синтеза
MA33948B1 (fr) Dérivés d&#39;acide 3-hétéroaroylamino-propionique substitues par oxygène et leur utilisation en tant qu&#39;agents pharmaceutiques.
BR122018074319B8 (pt) Método para preparar um composto de fórmula 14
MX348702B (es) Compuestos de ciclohexano sustituidos novedosos.
EA201590250A1 (ru) Производные карбамат/мочевины
IN2014KN01062A (pt)
ECSP13012914A (es) Síntesis de derivados de 2-carboxamida-cicloamino-urea
ME00927B (me) Novi postupak za sintezu agomelatina
BR112013009643A2 (pt) método para preparar n-(3-amino-quinoxalin-2-il)-sulfonamidas substituídas e seus intermediários n-(3-cloo-quinoxalin-2-il)-sulfonamidas
CY1112855T1 (el) Παραγωγα των πυρρολοπυριδινο-2-καρβοξαμιδιων, η παρασκευη τους και η θεραπευτικη εφαρμογη τους
BR112013006720A2 (pt) processo para preparação de inibidores de pan-cdk da fórmula (i) e intermediários da preparação
RU2011132708A (ru) Ароматические блок-сополиэфирсульфоны

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 3A, 4A E 5A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.